KMT2A and acute myeloid leukemia: CRISPR-gRNA targeting of this enhancer markedly inhibited the growth of AML cells irrespective of MLL mutation status and was associated with reduced BCL2 protein (Fig. 4g, h, Supplementary Fig. 10g–j).